Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
| Revenue (Most Recent Fiscal Year) | $36.50M |
| Net Income (Most Recent Fiscal Year) | $673.72M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 53.64 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.35 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 1917.72% |
| Net Margin (Trailing 12 Months) | 1798.26% |
| Return on Equity (Trailing 12 Months) | -2.75% |
| Return on Assets (Trailing 12 Months) | -2.52% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.50 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.17 |
| Book Value per Share (Most Recent Fiscal Quarter) | $27.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.38 |
| Diluted Earnings per Share (Trailing 12 Months) | $11.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.92M |
| Free Float | 55.06M |
| Market Capitalization | $1.99B |
| Average Volume (Last 20 Days) | 0.55M |
| Beta (Past 60 Months) | 0.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.93% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |